• Company advances transition to renewable electricity and sets a pathway to science-based emissions reductions

MINNEAPOLIS, Sept. 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today released its 2025 Corporate Sustainability Report, underscoring the company's commitment to advancing human health while protecting the planet.

"As a global innovator in life sciences, our mission is to improve the quality of life by catalyzing advances in science and medicine," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "We recognize that human health and the environment are intrinsically connected. By aligning our science with sustainable business practices, we not only unlock potential for better health outcomes, but also create lasting value for our employees, empower our customers, and strengthen the communities in which we live and work."

Highlights from Bio-Techne's 2025 Sustainability Report demonstrate measurable progress and bold commitments, including:

• Ongoing development and commercialization of breakthroughs in cancer, diabetes, neurodegenerative, autoimmune, and rare diseases—transforming diagnosis and care for millions worldwide.
• An estimated 40% reduction in Scope 1 and 2 emissions enterprise-wide, driven by the transition to 100% renewable electricity at the company's Minneapolis headquarters.⃰
• Commitment to set Scope 1, 2, and 3 greenhouse gas (GHG) reduction targets, with submission for validation to the Science Based Targets Initiative (SBTi) in 2026.
• Enhanced governance measures, including new Board oversight of artificial intelligence and completion of the first double materiality and climate assessments to guide sustainability priorities.
• Investment in culture and careers, with development and learning opportunities designed to empower teams under Bio-Techne's EPIC values—Empowerment, Passion, Innovation, and Collaboration

Bio-Techne's sustainability initiatives also fuel innovation across its life sciences portfolio, driving advances in cell therapy workflows, proteomic analytical instruments, spatial biology, and precision diagnostics—all developed with increased emphasis on efficiency and resource-conscious design.

"Our customers trust us to advance science responsibly, and we know that starts with our people," added Kelderman. "This report underscores our commitment to protecting the environment, supporting our employees and communities, and creating a workplace where diverse perspectives drive innovation and lasting impact."

The full 2025 Sustainability Report is available in the Corporate and Social Responsibility section of Bio-Techne's website.

^*Based on Scope 1 and 2 market-based greenhouse gas emissions.

About Bio-Techne

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at LinkedIn, X, or YouTube.

Contact:

Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
David Clair, Vice President, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.